Multidisciplinary Approaches to Paraneoplastic LEMS: Insights for Healthcare Decision-Makers : Episode 5
Opinion
Video
Team- and System-Based Approaches to Managing LEMS and Ensuring Access
A panelist discusses how comprehensive care coordination between specialists, proactive adverse effect management, and innovative care models can optimize treatment outcomes for Lambert-Eaton myasthenic syndrome (LEMS) patients, particularly those with dual diagnoses like small cell lung cancer (SCLC), while ensuring both clinical effectiveness and cost-efficiency through managed care strategies.
Video content above is prompted by the following:
- How can health care teams proactively manage adverse effects associated with treatments like amifampridine?
- How can managed care organizations facilitate timely access to LEMS therapies while ensuring cost-effectiveness?
- What strategies can improve communication and coordination between oncologists, neurologists, and pharmacists in managing dual-diagnosis patients?
- What innovative care models have shown promise in improving outcomes for patients with dual diagnoses like SCLC and LEMS?
Related Videos
Related Content
